問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of General Surgery

Division of Others-

Division of Others-

Division of Hematology & Oncology

Division of General Surgery

Division of Hematology & Oncology

Division of Others-

Division of Thoracic Medicine

更新時間：2023-09-19

蔡文銓
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

24Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡文銓

List

36Cases

2018-01-15 - 2029-06-30

Phase III

Active
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB(T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    KEYTRUDA

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting4Sites

2019-12-01 - 2024-12-31

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2022-03-01 - 2022-08-04

Phase I/II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Terminated3Sites

2023-05-01 - 2034-07-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2023-07-01 - 2031-11-06

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Recruiting12Sites

2023-07-31 - 2029-02-28

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Recruiting12Sites

2024-02-06 - 2029-08-30

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2025-01-01 - 2028-12-31

Others

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Not yet recruiting2Sites

2021-04-01 - 2027-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Not yet recruiting17Sites

2021-12-01 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB